Cantor Fitzgerald Reaffirms Overweight Rating for Kura Oncology (NASDAQ:KURA)

Cantor Fitzgerald reaffirmed their overweight rating on shares of Kura Oncology (NASDAQ:KURA) in a report issued on Monday, Benzinga reports.

Several other brokerages have also weighed in on KURA. Wedbush restated an outperform rating and issued a $37.00 price objective on shares of Kura Oncology in a report on Friday, August 9th. Stifel Nicolaus reduced their target price on Kura Oncology from $28.00 to $26.00 and set a buy rating for the company in a report on Friday, August 9th. JMP Securities reiterated a market outperform rating and issued a $32.00 price target on shares of Kura Oncology in a research report on Monday, August 12th. StockNews.com lowered Kura Oncology from a hold rating to a sell rating in a research report on Thursday, August 22nd. Finally, HC Wainwright reiterated a buy rating and issued a $32.00 price target on shares of Kura Oncology in a research report on Monday, August 12th. One analyst has rated the stock with a sell rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of Moderate Buy and a consensus price target of $30.60.

Kura Oncology Trading Up 0.7 %

Shares of Kura Oncology stock opened at $19.88 on Monday. The company has a quick ratio of 14.94, a current ratio of 14.94 and a debt-to-equity ratio of 0.02. The firm has a market cap of $1.52 billion, a price-to-earnings ratio of -9.16 and a beta of 0.84. The business has a fifty day simple moving average of $20.28 and a 200-day simple moving average of $20.66. Kura Oncology has a fifty-two week low of $7.41 and a fifty-two week high of $24.17.

Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.59) earnings per share for the quarter, beating the consensus estimate of ($0.63) by $0.04. Kura Oncology’s quarterly revenue was up .0% compared to the same quarter last year. During the same period last year, the business posted ($0.53) earnings per share. On average, equities analysts forecast that Kura Oncology will post -2.45 EPS for the current fiscal year.

Institutional Investors Weigh In On Kura Oncology

Several hedge funds have recently bought and sold shares of KURA. SG Americas Securities LLC purchased a new stake in Kura Oncology in the 1st quarter worth about $110,000. Cape Investment Advisory Inc. purchased a new stake in Kura Oncology in the 4th quarter worth about $176,000. Quarry LP purchased a new stake in Kura Oncology in the 2nd quarter worth about $196,000. Saxon Interests Inc. purchased a new stake in Kura Oncology in the 1st quarter worth about $201,000. Finally, Entropy Technologies LP purchased a new stake in Kura Oncology in the 1st quarter worth about $218,000.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.